BIO-TECHNE Corp Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross
BIO-TECHNE Corp (TECH) had Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross of $329.00 thousand as of 2016-06-30, per its 10-K filed 2017-09-07.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross · last filed 2017-09-07
- 2016-06-30: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $329.00K.
- 2015-06-30: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $0.00.
| Period end | Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross |
|---|---|
| 2016-06-30 | $329.00K 10-K · filed 2017-09-07 |
| 2015-06-30 | $0.00 10-K · filed 2016-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |